Mucopolysaccharidosis type IVA (MPS IVA, or Morquio syndrome type A) is an inherited
metabolic lysosomal disease caused by the deficiency of the N-acetylglucosamine-6-sulfate …

Mucopolysaccharidoses (MPSs) constitute a heterogeneous group of lysosomal storage
disorders characterized by the lysosomal accumulation of glycosaminoglycans (GAGs) …

Lysosomal storage disorders (LSDs) are a group of monogenic diseases characterized by
progressive accumulation of undegraded substrates into the lysosome, due to mutations in …

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative
agent of Coronavirus disease 19 (COVID-19), is a novel human Coronavirus that is …

Abstract Mucopolysaccharidosis IVA (MPS IVA) is a lysosomal storage disorder (LSD)
caused by mutations in gene encoding for GALNS enzyme. Lack of GALNS activity leads to …

Mucopolysaccharidosis (MPS) IVA is a lysosomal storage disorder caused by mutations in
the GALNS gene that leads to the lysosomal accumulation of keratan sulfate (KS) and …

Abstract Mucopolysaccharidosis IV A (MPS IVA) is a lysosomal disorder caused by
mutations in the GALNS gene. Consequently, the glycosaminoglycans (GAGs) keratan …

The mucopolysaccharidoses (MPS) are a group of 11 lysosomal storage diseases (LSDs)
produced by mutations in the enzymes involved in the lysosomal catabolism of …

Several arylamide-based antiproliferative agents are known and some of them are currently
FDA-approved anticancer drugs. Provoked by the need to fill the existing room with new …

N-Acetylgalactosamine-6-sulfatase (GALNS) is an enzyme whose deficiency is related to the
lysosomal storage disease Morquio A. For the development of effective therapeutic …